Managing Symptoms and Coordinating Care
At a Glance
MPAN has no cure yet, so treatment focuses on controlling symptoms, preserving independence, and supporting quality of life through a coordinated team of specialists. Medicines and therapies are individualized, while unproven treatments should only be considered with a specialist or approved clinical trial.
Because there is currently no cure for MPAN, the goal of treatment is to manage symptoms, maintain independence, and provide the best possible quality of life. This is achieved through multidisciplinary care—a “team approach” where different specialists work together to address the physical, emotional, and practical challenges of the disease [1][2].
Building Your Care Team
An effective care team is tailored to your specific symptoms. You do not need every specialist at once, but establishing a baseline with the following professionals is common:
- Neurologist: Often a specialist in movement disorders or neurogenetics, they manage medications for stiffness and tremors [3].
- Physical Therapist (PT): Focuses on mobility, balance, and strengthening. Small studies suggest targeted exercises can help maintain independence [4].
- Occupational Therapist (OT): Helps with activities of daily living, like dressing or using a computer, and recommends assistive devices.
- Speech-Language Pathologist (SLP): Essential for managing dysarthria (speech) and dysphagia (swallowing) [5].
- Ophthalmologist: Monitors for optic atrophy and provides support for vision loss [6].
- Mental Health Professional: A psychologist or psychiatrist can help manage anxiety, depression, or cognitive changes [7].
Managing Movement Symptoms
Treatment for movement challenges in MPAN is individualized. What works for one person may not work for another.
Spasticity and Dystonia
For the muscle stiffness (spasticity) and involuntary contractions (dystonia) that are common in patients, doctors may use:
- Oral Medications: Muscle relaxants are often the first step, though they can cause sleepiness [2].
- Botulinum Toxin: In some NBIA cases, “Botox” injections into specific muscles can help reduce stiffness, relieve pain, and prevent contractures (permanent muscle shortening). Depending on where it is injected, side effects can include temporary weakness or worsening swallowing [8].
- Therapy: Daily stretching and the use of braces (orthotics) can help keep joints flexible, but these must be individualized by a qualified PT or orthotist to avoid pain, skin injury, or falls [4].
Parkinsonism and Levodopa
Some patients develop parkinsonism (tremors and slowed movement). Doctors may try a medication called levodopa [9].
- The Benefit: It may improve movement in some individuals.
- The Risk: In MPAN, levodopa can sometimes cause choreiform dyskinesia—involuntary, dance-like movements that can be as bothersome as the original symptoms. Other possible side effects include nausea, sleepiness, hallucinations, and low blood pressure [9]. Monitoring for these side effects is a key part of any trial.
Experimental and Investigational Treatments
You may hear about treatments like deferiprone, elamipretide, or antioxidants. It is important to understand that these are currently investigational for MPAN and not standard routine care. They should only be discussed with your specialist or within an approved clinical trial.
- Deferiprone (Iron Chelation): This drug aims to remove excess iron from the brain. While studied in other NBIA disorders, its effectiveness in MPAN is unproven (case reports are uncontrolled and conflicting). Importantly, deferiprone can cause agranulocytosis (a severe, life-threatening drop in white blood cells) and liver abnormalities, requiring strict specialist prescribing and weekly monitoring [10][11]. Do not attempt iron chelation on your own.
- Elamipretide: This drug focuses on improving mitochondrial health. While one case report explored its use, it is an investigational drug that requires large clinical trials to confirm safety and efficacy [5].
- Antioxidants (like N-acetylcysteine): These have shown promise in “rescuing” damaged cells in a laboratory setting, but there is no evidence yet that they provide a clinical benefit to humans with MPAN [12]. Over-the-counter supplements can have adverse effects and interact with other medications.
Preparing for Your First Appointment
To make the most of your time with a new specialist, bring the following:
- A copy of your genetic report showing the specific C19orf12 mutation.
- Recent MRI images on a disc (not just the written report).
- A “top three” list of the symptoms that affect your daily life most severely.
- A list of all current medications and supplements, including doses.
- A history of prior treatments and whether they helped or caused side effects.
Common questions in this guide
How is MPAN treated if there is no cure?
What specialists are usually part of an MPAN care team?
Could levodopa help MPAN-related parkinsonism?
Can botulinum toxin help MPAN stiffness or dystonia?
Are deferiprone, elamipretide, or antioxidants proven MPAN treatments?
What should I bring to my first MPAN specialist appointment?
Should someone with MPAN have a swallowing evaluation before major problems appear?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Which medical professional will act as the 'quarterback' to coordinate my multidisciplinary care team?
- 2.Is a trial of levodopa appropriate for my/my child's parkinsonism symptoms, and how will we monitor for choreiform dyskinesia?
- 3.What specific physical therapy exercises are safe, and how can we use orthotics correctly to prevent skin injury?
- 4.Can we schedule a baseline swallow evaluation with a speech-language pathologist, even if I haven't noticed major issues yet?
- 5.Are there any active clinical trials for MPAN that I/my child might be eligible for?
- 6.What are the risks and benefits of using botulinum toxin to manage my/my child's spasticity or dystonia?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (12)
- 1
Emerging Disease-Modifying Therapies in Neurodegeneration With Brain Iron Accumulation (NBIA) Disorders.
Iankova V, Karin I, Klopstock T, Schneider SA
Frontiers in neurology 2021; (12()):629414 doi:10.3389/fneur.2021.629414.
PMID: 33935938 - 2
Consensus clinical management guideline for beta-propeller protein-associated neurodegeneration.
Wilson JL, Gregory A, Kurian MA, et al.
Developmental medicine and child neurology 2021; (63(12)):1402-1409 doi:10.1111/dmcn.14980.
PMID: 34347296 - 3
Phenotype and natural history of mitochondrial membrane protein-associated neurodegeneration.
Iankova V, Sparber P, Rohani M, et al.
Brain : a journal of neurology 2024; (147(4)):1389-1398 doi:10.1093/brain/awad357.
PMID: 37831662 - 4
Rehabilitation for Mitochondrial Membrane Protein-Related Neurodegeneration: A Case Study.
Özçelep ÖF, Turhan A, Fi Dan S, Kandemir S
Cureus 2023; (15(12)):e50540 doi:10.7759/cureus.50540.
PMID: 38222195 - 5
Expanded-access use of elamipretide in a patient with membrane protein-associated neurodegeneration.
Patino J, Clearman AH, Miller L, Koenig MK
Clinical case reports 2024; (12(7)):e9116 doi:10.1002/ccr3.9116.
PMID: 38919884 - 6
Retinal and optic nerve abnormalities in neurodegeneration associated with mutations in C19orf12 (MPAN).
Langwinska-Wosko E, Skowronska M, Kmiec T, Czlonkowska A
Journal of the neurological sciences 2016; (370()):237-240 doi:10.1016/j.jns.2016.09.046.
PMID: 27772766 - 7
Case Report: Identification of a De novo C19orf12 Variant in a Patient With Mitochondrial Membrane Protein-Associated Neurodegeneration.
Yang Y, Zhang S, Yang W, et al.
Frontiers in genetics 2022; (13()):852374 doi:10.3389/fgene.2022.852374.
PMID: 35432442 - 8
Palliative care in 9 children with neurodegeneration with brain iron accumulation.
Dangel T, Kmieć T, Januszaniec A, Ważny B
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2020; (41(3)):653-660 doi:10.1007/s10072-019-04099-5.
PMID: 31758347 - 9
C19orf12 gene variants causing mitochondrial membrane protein-associated neurodegeneration (MPAN).
Kumari R, Holla VV, Sriram N, et al.
European journal of human genetics : EJHG 2025; (33(7)):878-886 doi:10.1038/s41431-024-01778-6.
PMID: 39755877 - 10
A novel C19ORF12 mutation in two MPAN sisters treated with deferiprone.
Chen S, Lai X, Fu J, et al.
BMC neurology 2023; (23(1)):134 doi:10.1186/s12883-023-03172-z.
PMID: 37004026 - 11
Precision Medicine in Neurodegeneration with Brain Iron Accumulation (NBIA) Disorders: An Update on Emerging Treatments.
Schneider SA, Garg D, Iankova V, Klopstock T
Movement disorders clinical practice 2026; doi:10.1002/mdc3.70736.
PMID: 42429179 - 12
C19orf12 ablation causes ferroptosis in mitochondrial membrane protein-associated with neurodegeneration.
Shao C, Zhu J, Ma X, et al.
Free radical biology & medicine 2022; (182()):23-33 doi:10.1016/j.freeradbiomed.2022.02.006.
PMID: 35182730
This page is for informational purposes only and does not constitute medical advice. Discuss MPAN medications, therapies, supplements, and clinical trials with your neurologist and care team.
Get notified when new evidence is published on Mitochondrial membrane protein-associated neurodegeneration.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.